Bayer Sees Asia Pacific As Biggest Sales Growth Potential
This article was originally published in PharmAsia News
Executive Summary
Bayer Schering Pharma is looking to the Asia Pacific region for sales growth in the next few years in the high double digits. Already, the region accounts for more than 9 percent of the company's global sales this year. The head of the region's unit of Germany's Bayer AG said Asia Pacific was the main region of growth for Bayer Schering Parma in 2007, increasing by more than 26 percent. (Click here for more
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.